vTv Therapeutics (NASDAQ:VTVT) Posts Earnings Results, Misses Expectations By $0.08 EPS

Key Points

• vTv Therapeutics reported a quarterly EPS loss of $1.05, missing analysts’ consensus estimate by $0.08.
• Shares rose $0.22 to $34.61 during Thursday trading, while the company’s stock has ranged from $14.00 to $44.00 over the past year. Institutional investors own 17.51% of the shares.
• Analysts maintain a generally positive outlook, with a consensus “Moderate Buy” rating and an average price target of $55.83; recent targets range as high as $67.00.

vTv Therapeutics (NASDAQ:VTVT - Get Free Report) announced its quarterly earnings results on Thursday. The biotechnology company reported ($1.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.97) by ($0.08), Zacks reports.

vTv Therapeutics Stock Performance

Shares of VTVT traded up $0.22 during mid-day trading on Thursday, reaching $34.61. 139,960 shares of the company were exchanged, compared to its average volume of 100,056. The business has a 50 day simple moving average of $33.36 and a two-hundred day simple moving average of $34.80. The stock has a market capitalization of $136.36 million, a PE ratio of -37.21 and a beta of 0.28. vTv Therapeutics has a 52 week low of $14.00 and a 52 week high of $44.00.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the company. Goldman Sachs Group Inc. bought a new stake in shares of vTv Therapeutics in the 4th quarter valued at $221,000. Geode Capital Management LLC raised its stake in vTv Therapeutics by 84.3% during the fourth quarter. Geode Capital Management LLC now owns 28,194 shares of the biotechnology company's stock worth $1,128,000 after buying an additional 12,896 shares during the last quarter. Finally, 683 Capital Management LLC bought a new position in vTv Therapeutics during the fourth quarter worth $731,000. Institutional investors own 17.51% of the company's stock.

Analysts Set New Price Targets

A number of brokerages have weighed in on VTVT. Wall Street Zen upgraded shares of vTv Therapeutics from a "hold" rating to a "buy" rating in a research report on Saturday, May 16th. Rodman & Renshaw began coverage on vTv Therapeutics in a report on Tuesday, June 30th. They set a "buy" rating and a $67.00 price target on the stock. BTIG Research upped their price objective on vTv Therapeutics from $49.00 to $57.00 and gave the company a "buy" rating in a research note on Thursday, July 16th. HC Wainwright dropped their price objective on shares of vTv Therapeutics from $45.00 to $42.00 and set a "buy" rating for the company in a report on Thursday. Finally, Weiss Ratings upgraded shares of vTv Therapeutics from a "sell (d-)" rating to a "sell (d+)" rating in a research report on Monday, May 18th. Six equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, vTv Therapeutics has a consensus rating of "Moderate Buy" and a consensus price target of $55.83.

About vTv Therapeutics

vTv Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Westport, Connecticut, focused on discovering and developing orally administered small-molecule therapies for chronic diseases. Employing its proprietary medicinal chemistry platform, the company seeks to generate novel compounds that modulate key disease pathways while optimizing safety and pharmacokinetic properties.

The company's lead candidate, azeliragon (TTP488), is an oral inhibitor of the receptor for advanced glycation end products (RAGE) and has completed Phase II/III clinical evaluation in early-stage Alzheimer's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source